Community Practice Connections™: Leveraging Evolving Data Sets to Inform Treatment Decision-Making in Advanced RCC: An Expert Tumor Board Discussion

Community Practice Connections™: Leveraging Evolving Data Sets to Inform Treatment Decision-Making in Advanced RCC: An Expert Tumor Board Discussion is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with RCC are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This online activity is based on a live activity that was held adjunct to the 2019 annual oncology meeting in Chicago. It features video interviews with an esteemed faculty of internationally renowned experts in the treatment of patients with advanced renal cell carcinoma (RCC). Throughout this activity, these experts provide an in-depth review of the clinical impact of recent and emerging trial data for monotherapies and combination approaches in RCC. A series of tightly integrated case presentations illuminate RCC treatment decisions related to sequencing and switching based on patient and disease characteristics. Adverse events and their management are included in the commentary. Additionally, future directions in the field are addressed and considered in the context of how recent developments and highly anticipated trials may soon shape future care. Don’t miss this valuable opportunity to improve your practice!

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the biologic rationale for use of targeted agents and immunotherapies, as single agents and in combination, to treat renal cell carcinoma (RCC)
• Analyze practice-changing and emerging data from clinical trials of systemic therapies for use across multiple lines of therapy for advanced RCC
• Integrate knowledge of the safety profile of systemic therapies and best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC
• Consider the efficacy and safety of single-agent and combination systemic therapies, as well as patient and disease characteristics and patient preferences, as a part of shared decision-making for patients with metastatic RCC.